Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • onconaut
    Junior Member
    • Aug 2012
    • 7

    #1

    WES - how deep do you sequence your germline control

    Hello Seqers,

    we currently do WES with a mean coverage of ~120x for tumor as well as the germline samples. Since we only use the germline to help us with the somatic alteration calls I was thinking about cutting the coverage of the germline samples in half to free up some real estate on the flowcell. Does any one have experience with this?

    Thanks, O.
  • Bukowski
    Senior Member
    • Jan 2010
    • 388

    #2
    We'd normally do 50x on the normal and 100x+ on the tumour - I think that's quite a common strategy.

    Comment

    • bilyl
      Member
      • Aug 2013
      • 52

      #3
      It depends on your downstream processes. If you are simply calling SNVs then it doesn't really matter. But for other applications (eg. CNVs), many programs prefer to have similar coverage between your tumor and normal. Even if they don't require it, you are getting rid of other sources of variation (eg. by capturing the same amount of DNA in the same exome hyb reaction).

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        16S/ITS Profiling vs. Shotgun Metagenomics: What Changes in Your Workflow?
        by SEQadmin2




        NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...
        Today, 06:46 AM
      • SEQadmin2
        Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
        by SEQadmin2



        Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

        Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
        ...
        10-14-2026, 09:55 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, 10-28-2026, 09:57 AM
      0 responses
      22 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-28-2026, 09:51 AM
      0 responses
      14 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-22-2026, 11:13 AM
      0 responses
      67 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-22-2026, 10:48 AM
      0 responses
      47 views
      0 reactions
      Last Post SEQadmin2  
      Working...